🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Looking for a dynamic and world-class environment to start your independent research group? The Department of Biochemistry at the University of Oxford has an open call for Research Fellows (bioch.ox.ac.uk/jobs) in a wide range of research themes. Come join us! (and retweet!)

Perspective on exciting work by Kasper Fugger et al from Stephen West group in Crick. Where does modified bases go after DNA repair kindly asks them to leave DNA? How it could help to treat cancer? science.sciencemag.org/content/372/65…

So pleased to see our work on BAP1, H2AK119ub1, and gene regulation out today Genes & Development . A great team effort from Dr Nadya Fursova Neil Blackledge @ahturberfield @AnnaLastuvkova Miles Huseyin @PaulaDobrinic! Well done everyone! #Polycomb genesdev.cshlp.org/content/early/…

Ludwig Oxford’s Yang Shi, co-organizer of the #LudwigOxfordSymposium, kicked off day #2 of the meeting, which will cover subjects ranging from the mechanisms by which epigenetic changes drive cancer to the development of new diagnostics to epigenetic targets for drugs, and more.

Read the News&Views by Skirmantas Kriaucionis Skirmantas Kriaucionis: LKB1 cooperates with Sox17 to drive metastasis free access: rdcu.be/cruJp nature.com/articles/s4155…

Do you want to start your own independent research group in a supportive and world class research environment? The Department of Biochemistry in Oxford is seeking candidates to sponsor for Fellowships. bioch.ox.ac.uk/jobs

Great to see @emmy_dimitrova’s work out this morning. Nice team effort and fun working with deWitLab. New insight into the role of CDK-Mediator and #polycomb in poising/priming genes for induction. Tweetorial and link to paper below👇

Great opportunity for a Post-Doc Research Scientist in Skirmantas Kriaucionis and Stefan Constantinescu’s groups at Ludwig Nuffield Department of Medicine. Apply by December 6 bit.ly/3wuSDp0

Great to see the final version of Neil’s Neil Blackledge review out! #polycomb

This was a fun and exciting collaboration, so great to see it out!

Great to see Amy Hughes work on bioRxiv! If you are interested in CpG islands and transcription regulation check this out. Amy finds an interesting new role for CpG islands and SET1 complexes in counteracting termination by ZC3H4 complexes.👇 biorxiv.org/content/10.110…

Do [CA]n (CA repeats) mediate MeCP2 function? Follow this thread to know more 🧵 Our recently published critique ⚠️ of a Science Magazine article with open, constructive and fair peer review in LifeScienceAlliance 🙏 to all co-authors @WTcell Skirmantas Kriaucionis life-science-alliance.org/content/5/12/e…

Congratulations and welcome to the Ludwig Oxford, Richard!

Postdoctoral Computational Biologist position available in Parinaz Mehdipour’s group in cancer epigenetics and epitranscriptomics at Ludwig University of Oxford. Apply by November 23 bit.ly/3DC44Az

Why have so few cancer driver mutations been characterized in the non-coding genome so far? Excited to share our method Dr.Nod, where we use tissue-matched epigenome as a key to unlock the mystery of non-coding cancer drivers. 🧬🗝️ Nucleic Acids Res [1/23]🧵 academic.oup.com/nar/advance-ar…

I’m very proud of Amy Hughes and the rest of the team Department of Biochemistry at Oxford University on the final published version of our paper Nature Communications !🍾🎉 nature.com/articles/s4146… a few details about the paper below if you are interested👇

Cost of having DNA methylation: DNA replication by DNA polymerase epsilon is a source of C to T mutations in CpGs, especially methylated ones. This expands our understanding of one of the most widespread endogenous mutational mechanisms. nature.com/articles/s4158…

What is the most common type of mutations, causing cancer and genetic diseases? C to T mutations in CpGs: Signature 1. What is the best understood mutational signature? Signature 1. Or is it? Results of over 8 years of our work is finally out! 🧵1/ nature.com/articles/s4158…

Different patients can have unique enhancers driving gene expression in their leukemias: Enhancer heterogeneity in acute lymphoblastic leukemia drives differential gene expression between patients biorxiv.org/content/10.110…